Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SAVA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-0.51
vs -0.24
Q4.22
N/A
-0.47
vs -0.35
Q1.23
N/A
-0.58
vs -0.44
Q2.23
N/A
-0.63
vs -0.48
Q3.23
N/A
-0.61
vs -0.51
Q4.23
N/A
-0.50
vs -0.47
Q1.24
N/A
-1.41
vs -0.58
Q2.24
N/A
-1.28
vs -0.63
Q3.24
N/A
-0.58
vs -0.61
Q4.24
N/A
-0.57
vs -0.50
Sales Growth
YoY
Current
Estimates
Q3.22
NA
NA vs NA
Q4.22
-800%
-1800.00 vs -200
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
+130544%
2.3M vs -1800
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 2.3M
Return on Equity
QoQ
Q1.23
-11%
-0.11
vs -0.08
Q2.23
-15%
-0.15
vs -0.11
Q3.23
-17%
-0.17
vs -0.15
Q4.23
-15%
-0.15
vs -0.17
Q1.24
+32%
0.32
vs -0.15
Q2.24
+3%
0.03
vs 0.32
Q3.24
-17%
-0.17
vs 0.03
Q4.24
-19%
-0.19
vs -0.17
Institutionnal Ownership
QoQ
Q1.23
162
162
vs 176
-8%
Q2.23
170
170
vs 162
5%
Q3.23
163
163
vs 170
-4%
Q4.23
173
173
vs 163
6%
Q1.24
165
165
vs 173
-5%
Q2.24
169
169
vs 165
2%
Q3.24
191
191
vs 169
13%
Q4.24
171
171
vs 191
-10%
zacks.com
8 hours ago
zacks.com
11 hours ago
reuters.com
15 hours ago
Quote Panel
Key Metrics
Forecast
NaN%2025-Revenue
8%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Wells Fargo
upgradePrevious: Not converted
2024-10-08
Now: Buy
Wedbush
upgradePrevious: Not converted
2024-10-08
Now: Outperform
H.C. Wainwright
upgradePrevious: Neutral
2024-10-08
Now: Buy
H.C. Wainwright
downgradePrevious: Buy
2024-07-01
Now: Neutral
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.04 ( 2.87%)
Relative Strenght
4
Volume Buzz
-77%
Earning Acce
Yes
Dist 52w H.
96%Relative Strength
SAVA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SAVA compares to sector?
